Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Endocrinological Investigation

• Publication date

  2016-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40618-015-0339-yPMID 26142740
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic Inhibition of PDE5 Limits Pro-Inflammatory Monocyte-Macrophage Polarization in Streptozotocin-Induced Diabetic Mice

  2015cited by this paper
• Inhibition of type 5 phosphodiesterase counteracts β2-adrenergic signalling in beating cardiomyocytes.

  2015cited by this paper
• PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer.

  2015influential reference
• Effects of Sildenafil on Ventricular and Vascular Function in Heart Failure With Preserved Ejection Fraction

  2015influential reference
• Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis.

  2015influential reference
• PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials.

  2014cited by this paper
• Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials

  2014influential reference
• PDE5 inhibitor efficacy is estrogen dependent in female heart disease.

  2014cited by this paper
• Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor β-induced Smad signaling

  2014cited by this paper
• Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.

  2014influential reference
• Tadalafil Prevents Acute Heart Failure with Reduced Ejection Fraction in Mice

  2014cited by this paper
• Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

  2013influential reference
• Sildenafil in Heart Failure (SilHF). An investigator‐initiated multinational randomized controlled clinical trial: rationale and design

  2013cited by this paper
• Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction in Patients With Preserved Ejection Fraction: The Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) Trial

  2013cited by this paper
• Avanafil: A Review of Its Use in Patients with Erectile Dysfunction

  2013cited by this paper
• An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors

  2013cited by this paper
• Chronic Inhibition of cGMP Phosphodiesterase 5A Improves Diabetic Cardiomyopathy: A Randomized, Controlled Clinical Trial Using Magnetic Resonance Imaging With Myocardial Tagging

  2012cited by this paper
• Impact of Sildenafil on Echocardiographic Indices of Myocardial Performance After the Fontan Operation

  2012cited by this paper
• Cardiac uses of phosphodiesterase-5 inhibitors.

  2012cited by this paper
• Preconditioning by Phosphodiesterase‐5 Inhibition Improves Therapeutic Efficacy of Adipose‐Derived Stem Cells Following Myocardial Infarction in Mice

  2012cited by this paper
• Differential Expression of PDE5 in Failing and Nonfailing Human Myocardium

  2012cited by this paper
• An unusual adverse effect of sildenafil citrate: Acute myocardial infarction in a nitrate-free patient

  2012cited by this paper
• Cyclic GMP-dependent signaling in cardiac myocytes.

  2012cited by this paper
• Long-Term Effects of Sildenafil in a Rat Model of Chronic Mitral Regurgitation: Benefits of Ventricular Remodeling and Exercise Capacity

  2012influential reference
• Effects of Phosphodiesterase Type 5 Inhibition on Systemic and Pulmonary Hemodynamics and Ventricular Function in Patients With Severe Symptomatic Aortic Stenosis

  2012influential reference
• Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study

  2012influential reference
• Cardiac Role of Cyclic-GMP Hydrolyzing Phosphodiesterase Type 5: From Experimental Models to Clinical Trials

  2012influential reference
• Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long‐term cardiopulmonary exercise testing placebo‐controlled study

  2012influential reference
• Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo

  2012cited by this paper
• PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study

  2011cited by this paper
• Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.

  2011influential reference
• The controversial role of phosphodiesterase type 5 inhibitors in the treatment of premature ejaculation.

  2011cited by this paper
• Phosphodiesterase-5 Inhibition Mimics Intermittent Reoxygenation and Improves Cardioprotection in the Hypoxic Myocardium

  2011cited by this paper
• Effect of Phosphodiesterase Type 5 Inhibition on Microvascular Coronary Dysfunction in Women: A Women's Ischemia Syndrome Evaluation (WISE) Ancillary Study

  2011cited by this paper
• Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway.

  2011cited by this paper
• Ventilatory efficiency and dyspnea on exertion improvements are related to reduced pulmonary pressure in heart failure patients receiving Sildenafil.

  2010cited by this paper
• PDE5A suppression of acute β-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation

  2010cited by this paper
• Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy

  2010cited by this paper
• Phospholemman Ser69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury

  2010cited by this paper
• Phosphorylation of TRPC6 Channels at Thr69 Is Required for Anti-hypertrophic Effects of Phosphodiesterase 5 Inhibition*

  2010cited by this paper
• Phosphodiesterase-5 Inhibitor, Tadalafil, Protects Against Myocardial Ischemia/Reperfusion Through Protein-Kinase G–Dependent Generation of Hydrogen Sulfide

  2009cited by this paper
• Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.

  2009cited by this paper
• cGMP-Hydrolytic Activity and Its Inhibition by Sildenafil in Normal and Failing Human and Mouse Myocardium

  2009cited by this paper
• Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice.

  2009cited by this paper
• Long-acting phosphodiesterase-5 inhibitor, tadalafil, induces sustained cardioprotection against lethal ischemic injury.

  2009cited by this paper
• Sildenafil treatment of subacute ischemic stroke: a safety study at 25-mg daily for 2 weeks.

  2009cited by this paper
• Six months of Sildenafil therapy improves heart rate recovery in patients with heart failure.

  2009cited by this paper
• Dexamethasone but not tadalafil improves exercise capacity in adults prone to high-altitude pulmonary edema.

  2009cited by this paper
• Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study

  2009cited by this paper
• Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.

  2008cited by this paper
• Sildenafil and phosphodiesterase-5 inhibitors for heart failure

  2008cited by this paper
• Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs

  2008cited by this paper
• Essential role of mitochondrial Ca2+-activated and ATP-sensitive K+ channels in sildenafil-induced late cardioprotection.

  2008cited by this paper
• Effect of cyclosporine on reperfusion injury in acute myocardial infarction.

  2008cited by this paper
• Integrating evidence from multiple sources to evaluate post-approval safety: an example of sildenafil citrate and cardiovascular events

  2008cited by this paper
• Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial.

  2008cited by this paper
• Protein Kinase G-dependent Cardioprotective Mechanism of Phosphodiesterase-5 Inhibition Involves Phosphorylation of ERK and GSK3β*

  2008cited by this paper
• Vascular System: Role of Nitric Oxide in Cardiovascular Diseases

  2008cited by this paper
• Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility

  2007cited by this paper
• Diabetes Abolishes Sildenafil-Induced cGMP-Dependent Protein Kinase-I Expression and Cardioprotection

  2007cited by this paper
• Anti-ischemic effects of sildenafil, vardenafil and tadalafil in heart

  2007cited by this paper
• Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice.

  2007influential reference
• Long-term use of sildenafil in the therapeutic management of heart failure.

  2007cited by this paper
• Acute Myocardial Infarction following Sildenafil Intake in a Nitrate-Free Patient without Previous History of Coronary Artery Disease

  2007cited by this paper
• Cyclic GMP-dependent Protein Kinase Iα Attenuates Necrosis and Apoptosis Following Ischemia/Reoxygenation in Adult Cardiomyocyte*

  2006cited by this paper
• Controversies in ventricular remodelling.

  2006cited by this paper
• The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure

  2006cited by this paper
• Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia.

  2006cited by this paper
• Enhanced Cardioprotection Against Ischemia-Reperfusion Injury with Combining Sildenafil with Low-Dose Atorvastatin

  2006cited by this paper
• Sildenafil Improves Exercise Hemodynamics and Oxygen Uptake in Patients With Systolic Heart Failure

  2006cited by this paper
• Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications.

  2005cited by this paper
• Sildenafil citrate therapy for pulmonary arterial hypertension.

  2005cited by this paper
• Erectile dysfunction in aging men: testosterone role in therapeutic protocols.

  2005cited by this paper
• Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans.

  2005cited by this paper
• Phosphodiesterase-5 Inhibition With Sildenafil Attenuates Cardiomyocyte Apoptosis and Left Ventricular Dysfunction in a Chronic Model of Doxorubicin Cardiotoxicity

  2005cited by this paper
• Phosphodiesterase-5 Inhibitor Sildenafil Preconditions Adult Cardiac Myocytes against Necrosis and Apoptosis

  2005cited by this paper
• Androgens, cardiovascular disease and osteoporosis.

  2005cited by this paper
• Effect of sildenafil on cardiac performance in patients with heart failure.

  2005cited by this paper
• Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.

  2005cited by this paper
• Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk.

  2005cited by this paper
• Sildenafil Inhibits β-Adrenergic–Stimulated Cardiac Contractility in Humans

  2005cited by this paper
• Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

  2005cited by this paper
• Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24 h after oral administration in dogs

  2004cited by this paper
• Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.

  2004cited by this paper
• Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension

  2004cited by this paper
• cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism

  2004cited by this paper
• Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial.

  2004cited by this paper
• Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.

  2004cited by this paper
• Long-Term Inhibition of Rho-Kinase Suppresses Left Ventricular Remodeling After Myocardial Infarction in Mice

  2004cited by this paper
• The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure.

  2004cited by this paper
• Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina.

  2003cited by this paper
• Intravenous Sildenafil Is a Potent Pulmonary Vasodilator in Children With Congenital Heart Disease

  2003cited by this paper
• Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003.

  2003cited by this paper
• Sildenafil citrate does not affect cardiac contractility in human or dog heart

  2003cited by this paper
• Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy.

  2003cited by this paper
• Sildenafil Induces Delayed Preconditioning Through Inducible Nitric Oxide Synthase–Dependent Pathway in Mouse Heart

  2003cited by this paper
• Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial.

  2003cited by this paper
• Sildenafil Effects on Exercise, Neurohormonal Activation, and Erectile Dysfunction in Congestive Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Study Followed by a Prospective Treatment for Erectile Dysfunction

  2002cited by this paper
• The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia.

  2002cited by this paper
• Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits.

  2002influential reference

• The rewiring of cAMP/cGMP and LDH signalling drives cardiac hypertrophy in Pde5a−/− mice

  2025cites this paper
• Future perspectives for PDE5 inhibitors bridging the gap between cardiovascular health and psychological status

  2025cites this paper
• Contemporary Management of Raynaud’s Phenomenon

  2024cites this paper
• The increasing role of PDE5Is in men with diabetes and cardiovascular disease

  2023cites this paper
• Phytotherapic approach in menopause: light and darkness.

  2022cites this paper
• Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial

  2022cites this paper
• Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure

  2022cites this paper
• Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine—a possible prevention strategy for COVID-19?

  2022cites this paper
• The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders

  2022cites this paper
• Can myocardial performance index predict early cardiac risks in erectile dysfunction?

  2020cites this paper
• Novel treatments for diastolic heart failure

  2020cites this paper
• Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor?

  2020cites this paper
• Testosterone and the Heart

  2019cites this paper
• Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome.

  2019cites this paper
• An update on the drug safety of treating erectile dysfunction

  2019cites this paper
• Effect of PDE5 inhibitor on isoproterenol-induced cardiomyocyte hypertrophy in neonatal rats

  2019cites this paper
• British Society for Sexual Medicine Guidelines on the Management of Erectile Dysfunction in Men-2017.

  2018cites this paper
• Type 2 Diabetes and Testosterone Therapy

  2018cites this paper
• Could chronic Vardenafil administration influence the cardiovascular risk in men with type 2 diabetes mellitus?

  2018cites this paper
• Basic Aspects of Cardiac Remodelling

  2018cites this paper
• Roles of A-Kinase Anchoring Proteins and Phosphodiesterases in the Cardiovascular System

  2018cites this paper
• Phosphodiesterase 2 as a Therapeutic Target for Heart Failure: Is Upregulation an Option?

  2017cites this paper
• Effects of daily tadalafil on lower urinary tract symptoms in young men with multiple sclerosis and erectile dysfunction: a pilot study

  2017cites this paper
• Impacts of Medications on Male Fertility

  2017cites this paper
• Phosphodiesterase Inhibitors (PDE Inhibitors) and Male Reproduction.

  2017cites this paper
• The Woman's Heart: Insights into New Potential Targeted Therapy.

  2017cites this paper
• Angiopoietin-1 and Angiopoietin-2 in metabolic disorders: therapeutic strategies to restore the highs and lows of angiogenesis in diabetes

  2016cites this paper
• Effects of chronic administration of the phosphodiesterase inhibitor vardenafil on serum levels of adrenal and testicular steroids in men with type 2 diabetes mellitus

  2016cites this paper
• Predictors and clinical consequences of starting androgen therapy in men with low testosterone: results from the SIAMO-NOI registry

  2016cites this paper
• Subclinical left ventricular deterioration in patients with erectile dysfunction

  2016cites this paper
• Effects of tadalafil treatment combined with physical activity in patients with low onset hypogonadism: results from a not-randomized single arm phase 2 study

  2016cites this paper